Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck
Por:
Szturz, P, Fuereder, T, Guo, Y, Licitra, L, Mesia, R, Ivanyi, P, Falco, A, Tahara, M, Solbes, MN, Venturini, F and Bossi, P
Publicada:
1 abr 2025
Ahead of Print:
1 mar 2025
Resumen:
Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes for patients. Most national and regional guidelines recommend first-line therapy with an immune checkpoint inhibitor (with or without chemotherapy) or a cetuximab-based regimen, by assessment of expression levels of the biomarker programmed cell death-ligand 1 (PD-L1). However, patient- and tumor-specific factors, including the patient's age, comorbidities, performance status, and tumor burden, kinetics and spread also need to be considered to optimize treatment in the first line. Additionally, with increasing availability of newer therapies globally, it is crucial to customize the subsequent second- or later-line therapy based on patient characteristics, including the previous therapy received. This review highlights the factors that should be considered for treatment decisionmaking in patients with R/M SCCHN. It also summarizes the current evidence for clinical outcomes based on treatment sequencing and provides guidance on choosing an optimal treatment regimen for patients in the firstline treatment setting and beyond.
Filiaciones:
Szturz, P:
Univ Lausanne UNIL, Dept Oncol, Rue Bugnon 46, CH-1011 Lausanne, Switzerland
Fuereder, T:
Lausanne Univ Hosp CHUV, Rue Bugnon 46, CH-1005 Lausanne, Switzerland
Guo, Y:
Med Univ Vienna, Dept Med 1, Div Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
Licitra, L:
Tongji Univ, Sch Med, Shanghai East Hosp, Dept Oncol, 1800 Yuntai Rd, Shanghai 200123, Peoples R China
Fdn IRCCS Ist Nazl Tumori Milan, Via Giacomo Venezian, 1, I-20133 Milan, Italy
:
Univ Milan, Via Festa Perdono,7, I-20122 Milan, Italy
Ivanyi, P:
Inst Invest Ciencies Salut Germans Trias & Pujol I, Catalan Inst Oncol ICO, Med Oncol Dept, Badalona Appl Res Grp Oncol B ARGO Grp, Ctra Can Ruti,Cami de les Escoles,S N, Badalona 08916, Spain
Falco, A:
Hannover Med Sch, Claudia Schilling Comprehens Canc Ctr, Dept Hematol Hemostasis Oncol & Stem Cell Transpla, Carl Neuberg Str 1, D-30625 Hannover, Germany
Tahara, M:
Alexander Fleming Canc Inst, Dept Med Oncol, Head & Neck Unit, Cramer 1180,C1426, Autonoma Buenos Aires, Argentina
Solbes, MN:
Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, 6 Chome-5-1, Kashiwa, Chiba 2778577, Japan
Venturini, F:
Merck Healthcare KGaA, Frankfurter Str 250, D-64293 Darmstadt, Germany
Merck KGaA, Merck Serono SpA, Piazza Pigneto 9, Rome, Italy
Bossi, P:
Humanitas Univ, IRCCS Human Res Hosp, Dept Biomed Sci, Via Rita Levi Montalcini,4, I-20072 Milan, Italy
Green Submitted, Green Published, hybrid
|